ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2021 - 2024)
Historic Liabilities and Shareholders Equity for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $179.5 million.
- ProQR Therapeutics' Liabilities and Shareholders Equity rose 2098.05% to $179.5 million in Q4 2024 from the same period last year, while for Sep 2025 it was $179.5 million, marking a year-over-year increase of 2098.05%. This contributed to the annual value of $181.8 million for FY2024, which is 2188.19% up from last year.
- Latest data reveals that ProQR Therapeutics reported Liabilities and Shareholders Equity of $179.5 million as of Q4 2024, which was up 2098.05% from $148.4 million recorded in Q4 2023.
- Over the past 5 years, ProQR Therapeutics' Liabilities and Shareholders Equity peaked at $110.5 billion during Q1 2021, and registered a low of $122.7 million during Q3 2022.
- Its 4-year average for Liabilities and Shareholders Equity is $8.7 billion, with a median of $179.5 million in 2024.
- In the last 5 years, ProQR Therapeutics' Liabilities and Shareholders Equity crashed by 9980.68% in 2022 and then soared by 2597.08% in 2023.
- Over the past 4 years, ProQR Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $239.8 million in 2021, then dropped by 27.1% to $174.8 million in 2022, then fell by 15.12% to $148.4 million in 2023, then rose by 20.98% to $179.5 million in 2024.
- Its last three reported values are $179.5 million in Q4 2024, $148.4 million for Q4 2023, and $154.6 million during Q3 2023.